🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSELECT cost-effectiveness — looking for input Page 5

SELECT cost-effectiveness — looking for input

claudia_zurich Tue, Nov 11, 2025 at 1:22 PM 36 replies 1,506 viewsPage 5 of 8
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
Nov 23, 2025 at 5:45 PM#21

From the other side of the consultation, briefly.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 50 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

44 19SarahChen_PharmD, sarah.morrison, NeuroNate and 41 others
Reply Quote Save Share Report
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
Nov 25, 2025 at 11:13 PM#22
TinaHashiRN said:
Lp(a) and cardiovascular risk: a nuance that matters.

Same experience, arrived at from the opposite direction.

43 18Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 40 others
Reply Quote Save Share Report
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Nov 28, 2025 at 4:43 AM#23
TinaHashiRN said:
Lp(a) and cardiovascular risk: a nuance that matters.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 50 pg/mL (normal, cardiac function preserved)
  • Lp(a): 60 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 135 to 90 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

42 17bri_stats, pete_manc_UK, anna.melb_AU and 39 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Nov 30, 2025 at 10:14 AM#24
TinaHashiRN said:
Lp(a) and cardiovascular risk: a nuance that matters.
TinaHashiRN said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

Last edited: Nov 30, 2025 at 12:14 PM
41 16B12Beth, RickReta_CO, PharmHunterJen and 38 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Dec 2, 2025 at 3:46 PM#25

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

40 15pete_manc_UK, anna.melb_AU, mark_tokyo and 37 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register